Broadly Neutralizing Antibodies: Promising Tools in the Fight Against HIV

The Rockefeller University invites you to join us and learn about a promising new approach to combat HIV: Broadly Neutralizing Antibodies (bNAbs). Antibodies are Y-shaped proteins that are produced by the body’s immune system to fight infections. HIV bNAbs are powerful antibodies that can clear the virus from the blood and also facilitate the body’s ability to clear cells that hide the virus. Over the last few years, bNAb studies have shown promising results in their potential to prevent, control or suppress infection, safely and for prolonged periods of time. 

Learn about ongoing research with bNAbs and hear perspectives from scientists, doctors, research nurse practitioners, HIV advocates, and participants in clinical trials about their experiences with HIV research.

5:45 p.m.                     Registration opens

6:00 – 6:45 p.m           Refreshments and networking

6:45 p.m.                     Welcoming remarks

                                              -  Marina Caskey, M.D.

                                                Associate Professor of Clinical Investigation, The Rockefeller University

The Present and Future of HIV Prevention

          -  Mitchell Warren

            Executive Director at AIDS Vaccine Advocacy Coalition (AVAC)
                       

7 p.m.                          Targeting HIV with bNAbs: Towards Effective Prevention and a Potential Cure     
                                             -  Marina Caskey, M.D.

Associate Professor of Clinical Investigation, The Rockefeller University

7:30 – 8:30 p.m.          Panel discussion

What roles might broadly neutralizing antibodies play in HIV prevention, treatment or cure?

Why participate in research?

-        Kathy Anastos, M.D., Professor, Albert Einstein College of Medicine.

-        Pat Fast, M.D., Senior Technical Advisor at the International AIDS Vaccine Initiative

-        Sarah Schlesinger, M.D., Associate Professor of Clinical Investigation, The Rockefeller University

-        Timothy Wilkin, M.D., M.P.H., Associate Professor, Weill Cornell Medicine

-        Research participants who have enrolled in past or present trials to test strategies to prevent or treat HIV

8:30 p.m.                    Concluding remarks